1.A Simple and Fast Web Alignment Tool for Large Amount of Sequence Data.
Genomics & Informatics 2008;6(3):157-159
Multiple sequence alignment (MSA) is the most important step for many of biological sequence analyses, homology search, and protein structural assignments. However, large amount of data make biologists difficult to perform MSA analyses and it requires much computational time to align many sequences. Here, we have developed a simple and fast web alignment tool for aligning, editing, and visualizing large amount of sequence data. We used a cluster server installed ClustalW-MPI using web services and message passing interface (MPI). It also enables users to edit multiple sequence alignments for manual editing and to download the input data and results such as alignments and phylogenetic tree.
Sequence Alignment
;
Sequence Analysis
2.A High-fat Diet Induces a Loss of Midbrain Dopaminergic Neuronal Function That Underlies Motor Abnormalities.
Yunseon JANG ; Min Joung LEE ; Jeongsu HAN ; Soo Jeong KIM ; Ilhwan RYU ; Xianshu JU ; Min Jeong RYU ; Woosuk CHUNG ; Eungseok OH ; Gi Ryang KWEON ; Jun Young HEO
Experimental Neurobiology 2017;26(2):104-112
Movement defects in obesity are associated with peripheral muscle defects, arthritis, and dysfunction of motor control by the brain. Although movement functionality is negatively correlated with obesity, the brain regions and downstream signaling pathways associated with movement defects in obesity are unclear. A dopaminergic neuronal pathway from the substantia nigra (SN) to the striatum is responsible for regulating grip strength and motor initiation through tyrosine hydroxylase (TH) activity-dependent dopamine release. We found that mice fed a high-fat diet exhibited decreased movement in open-field tests and an increase in missteps in a vertical grid test compared with normally fed mice. This motor abnormality was associated with a significant reduction of TH in the SN and striatum. We further found that phosphorylation of c-Jun N-terminal kinase (JNK), which modulates TH expression in the SN and striatum, was decreased under excess-energy conditions. Our findings suggest that high calorie intake impairs motor function through JNK-dependent dysregulation of TH in the SN and striatum.
Animals
;
Arthritis
;
Brain
;
Diet, High-Fat*
;
Dopamine
;
Dopaminergic Neurons*
;
Hand Strength
;
JNK Mitogen-Activated Protein Kinases
;
Mesencephalon*
;
Mice
;
Obesity
;
Phosphorylation
;
Substantia Nigra
;
Tyrosine 3-Monooxygenase
3.Rationale and Design of the High Platelet Inhibition with Ticagrelor to Improve Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction (HEALING-AMI) Trial
Yongwhi PARK ; Si Wan CHOI ; Ju Hyeon OH ; Eun Seok SHIN ; Sang Yeub LEE ; Jeongsu KIM ; Weon KIM ; Jeong Won SUH ; Dong Heon YANG ; Young Joon HONG ; Mark Y CHAN ; Jin Sin KOH ; Jin Yong HWANG ; Jae Hyeong PARK ; Young Hoon JEONG ;
Korean Circulation Journal 2019;49(7):586-599
BACKGROUND AND OBJECTIVES: Impaired recovery from left ventricular (LV) dysfunction is a major prognostic factor after myocardial infarction (MI). Because P2Y12 receptor blockade inhibits myocardial injury, ticagrelor with off-target properties may have myocardial protection over clopidogrel. In animal models, ticagrelor vs. clopidogrel protects myocardium against reperfusion injury and improves remodeling after MI. We aimed to investigate the effect of ticagrelor on sequential myocardial remodeling process after MI. METHODS: High platelet inhibition with ticagrelor to improve LV remodeling in patients with ST-segment elevation MI (HEALING-AMI) is an investigator-initiated, randomized, open-label, assessor-blinded, multi-center trial done at 10 sites in Korea. Patients will be enrolled if they have ST-segment elevation MI (STEMI) treated with primary percutaneous coronary intervention and a planned duration of dual antiplatelet treatment of at least 6 months. Screened patients will be randomly assigned (1:1) using an internet-based randomization with a computer-generated blocking with stratification across study sites to either ticagrelor or clopidogrel treatment. The co-primary primary endpoints are LV remodeling index with three-dimensional echocardiography and the level of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) at 6 months representing post-MI remodeling processes. Changes of LV end-systolic/diastolic volume indices and LV ejection fraction between baseline and 6-month follow-up will be also evaluated. Analysis is per protocol. CONCLUSIONS: HEALING-AMI is testing the effect of ticagrelor in reducing adverse LV remodeling following STEMI. Our trial would show the benefit of ticagrelor vs. clopidogrel related to the recovery of post-MI LV dysfunction beyond potent platelet inhibition. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02224534
Blood Platelets
;
Echocardiography, Three-Dimensional
;
Follow-Up Studies
;
Humans
;
Korea
;
Models, Animal
;
Myocardial Infarction
;
Myocardium
;
Natriuretic Peptide, Brain
;
Percutaneous Coronary Intervention
;
Random Allocation
;
Reperfusion Injury
;
Ventricular Remodeling
4.Rationale and Design of the High Platelet Inhibition with Ticagrelor to Improve Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction (HEALING-AMI) Trial
Yongwhi PARK ; Si Wan CHOI ; Ju Hyeon OH ; Eun Seok SHIN ; Sang Yeub LEE ; Jeongsu KIM ; Weon KIM ; Jeong Won SUH ; Dong Heon YANG ; Young Joon HONG ; Mark Y CHAN ; Jin Sin KOH ; Jin Yong HWANG ; Jae Hyeong PARK ; Young Hoon JEONG ;
Korean Circulation Journal 2019;49(7):586-599
BACKGROUND AND OBJECTIVES:
Impaired recovery from left ventricular (LV) dysfunction is a major prognostic factor after myocardial infarction (MI). Because P2Y12 receptor blockade inhibits myocardial injury, ticagrelor with off-target properties may have myocardial protection over clopidogrel. In animal models, ticagrelor vs. clopidogrel protects myocardium against reperfusion injury and improves remodeling after MI. We aimed to investigate the effect of ticagrelor on sequential myocardial remodeling process after MI.
METHODS:
High platelet inhibition with ticagrelor to improve LV remodeling in patients with ST-segment elevation MI (HEALING-AMI) is an investigator-initiated, randomized, open-label, assessor-blinded, multi-center trial done at 10 sites in Korea. Patients will be enrolled if they have ST-segment elevation MI (STEMI) treated with primary percutaneous coronary intervention and a planned duration of dual antiplatelet treatment of at least 6 months. Screened patients will be randomly assigned (1:1) using an internet-based randomization with a computer-generated blocking with stratification across study sites to either ticagrelor or clopidogrel treatment. The co-primary primary endpoints are LV remodeling index with three-dimensional echocardiography and the level of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) at 6 months representing post-MI remodeling processes. Changes of LV end-systolic/diastolic volume indices and LV ejection fraction between baseline and 6-month follow-up will be also evaluated. Analysis is per protocol.
CONCLUSIONS
HEALING-AMI is testing the effect of ticagrelor in reducing adverse LV remodeling following STEMI. Our trial would show the benefit of ticagrelor vs. clopidogrel related to the recovery of post-MI LV dysfunction beyond potent platelet inhibition.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02224534
5.A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1nCoV-19 Vaccination
Seok Hyun KIM ; Soo Yong LEE ; Ga Yun KIM ; Ji Soo OH ; Jeongsu KIM ; Kook Jin CHUN ; Min Ho JU ; Chee-hoon LEE ; Yeo-Jeong SONG ; Joo-Young NA
Journal of Korean Medical Science 2022;37(13):e104-
Vaccines have become the mainstay of management against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) in the absence of effective antiviral therapy. Various adverse effects of COVID-19 vaccination have been reported, including cardiovascular complications such as myocarditis or pericarditis. Herein, we describe clinical records of a 63-year woman with fulminant myocarditis following ChAdOx1 nCoV-19 vaccination that was salvaged by heart transplantation. She complained chest pain, nausea, vomiting, and fever after the second vaccination. After the heart transplantation, the patient died due to necrotizing pneumonia on the 54th day of onset. Fulminant myocarditis is very rare after ChAdOx1 nCoV-19 vaccination but can be fatal.